Abstract
HBV RNA is a novel serum biomarker that reflects intrahepatic HBV covalently closed circular DNA (cccDNA) transcription activity. Serum HBV RNA levels among treatment-naïve adults during the natural history of chronic hepatitis B (CHB) and distinct liver histopathology statuses remain elusive. In our study, we include a total of 411 treatment-naïve CHB patients, among which 43 patients were HBeAg-positive immune-tolerant [IT(e+)], 84 patients were HBeAg-positive immune active [IA(e+)], 65 patients in HBeAg-negative immune active phases [IA(e−)], 149 patients were HBeAg-negative inactive phases [IC(e−)], and 70 patients were in Gray Zone (GZ). HBV RNA was measured in this cohort and its potential correlation with traditional serological markers and liver histopathology were analyzed. Our data showed that HBV RNA was strongly correlated with HBV DNA, HBeAg, HBsAg and ALT. Further subgroup analysis revealed a close correlation between HBV RNA and HBV DNA in patients in the IA (e+) and IA (e−) phases, but neither in IT(e+) nor IC(e−) phase. HBV RNA levels were consistently increased with the advanced degrees of hepatic inflammation, but not hepatic fibrosis. Of note, HBV RNA from HBeAg-positive patients negatively correlated with liver fibrosis, whereas HBV RNA from HBeAg-negative patients was weakly associated with liver inflammation. To sum up, serum HBV RNA shows a distinct profile among CHB patients in different immune statuses and hepatic histopathology stages/grades. Simultaneous testing of HBV RNA and traditional indicators might provide a comprehensive clinical assessment of CHB patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allweiss L, Dandri M (2017) The role of cccDNA in HBV maintenance. Viruses 9:156. https://doi.org/10.3390/v9060156
Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209–218. https://doi.org/10.1172/JCI24282
Bonacci M, Lens S, Mariño Z et al (2018) Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone. Aliment Pharmacol Ther 47:1397–1408. https://doi.org/10.1111/apt.14613
Butler EK, Gersch J, McNamara A et al (2018) Hepatitis B virus serum DNA and RNA levels in Nucleos(t)ide analog-treated or untreated patients during chronic and acute infection. Hepatology 68:2106–2117. https://doi.org/10.1002/hep.30082
Carey I, Gersch J, Wang B et al (2020) Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(T)ide analogue therapy. Hepatology 72:42–57. https://doi.org/10.1002/hep.31026
Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association (2019) The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Chin J Hepatol 35:2468–2669. https://doi.org/10.3760/cma.j.issn.1007-3418.2015.12.002
Coffin CS, Zhou K, Terrault NA (2019) New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection. Gastroenterology 156:355-368.e3. https://doi.org/10.1053/j.gastro.2018.11.037
Fanning GC, Zoulim F, Hou J, Bertoletti A (2019) Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov 18:827–844. https://doi.org/10.1038/s41573-019-0037-0
Ghany MG, King WC, Lisker-Melman M et al (2021) Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America. Hepatology 74:2395–2409. https://doi.org/10.1002/hep.32018
Giersch K, Allweiss L, Volz T et al (2017) Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol 66:460–462. https://doi.org/10.1016/j.jhep.2016.09.028
Henderson NC, Rieder F, Wynn TA (2020) Fibrosis: from mechanisms to medicines. Nature 587:555–566. https://doi.org/10.1038/s41586-020-2938-9
Höner zu Siederdissen C, Maasoumy B, Cornberg M (2017) What is new on HBsAg and other diagnostic markers in HBV infection. Best Pract Res Clin Gastroenterol 31:281–289. https://doi.org/10.1016/j.bpg.2017.04.009
Huang H, Wang J, Li W et al (2018) Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals. J Clin Virol 99–100:71–78. https://doi.org/10.1016/j.jcv.2017.12.016
Huang C, Li Q, Xu W et al (2020) Serum HBV RNA levels predict significant liver fibrosis in patients with chronic HBV infection. Discov Med 29:119–128
Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC (2008) Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47:1363–1370. https://doi.org/10.1002/hep.22109
Köck J, Theilmann L, Galle P, Schlicht H (1996) Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus: hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology 23:405–413. https://doi.org/10.1002/hep.510230303
Lai C-L, Wong D, Ip P et al (2017) Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol 66:275–281. https://doi.org/10.1016/j.jhep.2016.08.022
Liao H, Li L, Zheng WV et al (2022) Characteristics of HBV novel serum markers across distinct phases in treatment-naïve chronic HBV-infected patients. Dis Markers 2022:1–13. https://doi.org/10.1155/2022/4133283
Liu S, Zhou B, Valdes JD et al (2019) Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection. Hepatology 69:1816–1827. https://doi.org/10.1002/hep.30325
Liu S, Liu Z, Li W et al (2020) Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues. Aliment Pharmacol Ther 52:692–700. https://doi.org/10.1111/apt.15890
Lok ASF, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45:507–539. https://doi.org/10.1002/hep.21513
Mak L, Cloherty G, Wong DK et al (2021) HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy. Hepatology 73:2167–2179. https://doi.org/10.1002/hep.31616
Nassal M (2015) HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64:1972–1984. https://doi.org/10.1136/gutjnl-2015-309809
Nguyen MH, Wong G, Gane E et al (2020) Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev 33:e00046-e119. https://doi.org/10.1128/CMR.00046-19
Ren S, Wang W, Lu J et al (2022) Effect of the change in antiviral therapy indication on identifying significant liver injury among chronic hepatitis B virus infections in the grey zone. Front Immunol 13:1035923. https://doi.org/10.3389/fimmu.2022.1035923
Rockey DC, Caldwell SH, Goodman ZD et al (2009) Liver biopsy. Hepatology 49:1017–1044. https://doi.org/10.1002/hep.22742
Russo FP, Imondi A, Lynch EN, Farinati F (2018) When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. Dig Liver Dis 50:640–646. https://doi.org/10.1016/j.dld.2018.03.014
Schcuer J (1991) Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13:372–374. https://doi.org/10.1016/0168-8278(91)90084-o
Shen S, Xie Z, Cai D et al (2020) Biogenesis and molecular characteristics of serum hepatitis B virus RNA. PLoS Pathog 16:e1008945. https://doi.org/10.1371/journal.ppat.1008945
Tang LSY, Covert E, Wilson E, Kottilil S (2018) Chronic hepatitis B infection: a review. JAMA 319:1802. https://doi.org/10.1001/jama.2018.3795
Terrault NA, Bzowej NH, Chang K-M et al (2016) AASLD guidelines for treatment of chronic hepatitis B: hepatology, month 2015. Hepatology 63:261–283. https://doi.org/10.1002/hep.28156
Terrault N, Lok A, McMahon B et al (2018) Update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67:1560–1599. https://doi.org/10.1002/hep.29800
Tsuge M, Murakami E, Imamura M et al (2013) Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol 48:1188–1204. https://doi.org/10.1007/s00535-012-0737-2
van Bömmel F, van Bömmel A, Krauel A et al (2018) Serum HBV RNA as a predictor of peginterferon Alfa-2a response in patients with HBeAg-positive chronic hepatitis B. J Infect Dis 218:1066–1074. https://doi.org/10.1093/infdis/jiy270
Wang J, Yu Y, Li G et al (2018a) Natural history of serum HBV-RNA in chronic HBV infection. J Viral Hepat 25:1038–1047. https://doi.org/10.1111/jvh.12908
Wang J, Yu Y, Li G et al (2018b) Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol 68:16–24. https://doi.org/10.1016/j.jhep.2017.08.021
Wang X, Chi X, Wu R et al (2021) Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment. Virol J 18:4. https://doi.org/10.1186/s12985-020-01471-2
Wang J, Yan X, Zhu L et al (2023) Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone. Aliment Pharmacol Ther 57:464–474. https://doi.org/10.1111/apt.17272
World Health Organization (2021) World health statistics 2021: monitoring health for the SDGs, sustainable development goals. World Health Organization, Geneva
Yao K, Liu J, Wang J et al (2021) Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat 28:1025–1033. https://doi.org/10.1111/jvh.13511
Zhou J, Wang F-D, Wang M-L et al (2021) Antiviral therapy for chronic HBV infection with persistently normal alanine aminotransferase: controversy and consensus. Front Med (lausanne) 8:717125. https://doi.org/10.3389/fmed.2021.717125
Funding
This work received support from, Scientific Research Project of Jiangsu Health Commission (Grant No. M2022013), Medical Science and Technology Development Foundation, Nanjing Department of Health (Grant No. YKK22071), Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University (Grant Nos. 2021-LCYJ-PY-09 and 2022-LCYJ-PY-49).
Author information
Authors and Affiliations
Contributions
QX: Conceptualization, Methodology, Software, Investigation, Data Curation, Writing-Original Draft. HD: Methodology, Software, Investigation, Project Administration, Writing-Review & Editing. BT: Formal Analysis, Software. RH: Conceptualization, Data Curation. JW: Resources, Software. JZ: Resources,Validation. HL: Resources, Investigation. YC: Supervision, Funding Acquisition, Supervision, Administration, Data Curation. YY: Methodology, Data Curation, Administration. JW: Supervision, Administration.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Xu, Q., Ding, H., Bai, T. et al. Serum HBV RNA levels among untreated adults with chronic hepatitis B in distinct immune phases and liver histopathology statuses. J Mol Histol 54, 739–749 (2023). https://doi.org/10.1007/s10735-023-10162-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10735-023-10162-5